CEL-SCI Corp (CVM)

0.42
AMEX : Health Care
Prev Close 0.41
Day Low/High 0.41 / 0.42
52 Wk Low/High 0.33 / 0.75
Avg Volume 408.00K
Exchange AMEX
Shares Outstanding 145.35M
Market Cap 59.59M
EPS -0.40
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

CEL-SCI Announces The Closing Of Its $5 Million Registered Direct Offering

CEL-SCI Announces The Closing Of Its $5 Million Registered Direct Offering

CEL-SCI Corporation (NYSE MKT: CVM) announced that it has closed its previously announced registered direct offering with institutional investors.

CEL-SCI Announces $5 Million Registered Direct Offering

CEL-SCI Announces $5 Million Registered Direct Offering

CEL-SCI Corporation (NYSE MKT:CVM) today announced it has entered into a definitive agreement with institutional investors to purchase approximately 10 million shares of its common stock and warrants exercisable for up to...

CEL-SCI Corporation Reports Third Quarter Fiscal Year 2016 Financial Results

CEL-SCI Corporation Reports Third Quarter Fiscal Year 2016 Financial Results

CEL-SCI Corporation (NYSE MKT: CVM) reported financial results for the quarter ended June 30, 2016 and updates shareholders in regards to the upcoming date for the Company's arbitration hearing against its former Clinical...

CEL-SCI Reports Monthly Patient Enrollment In July For Its Phase 3 Head And Neck Cancer Trial

CEL-SCI Reports Monthly Patient Enrollment In July For Its Phase 3 Head And Neck Cancer Trial

CEL-SCI Corporation (NYSE MKT:CVM) ("CEL SCI" or the "Company") today announced that during the month of July it has enrolled 29 patients in its ongoing Phase 3 trial of its investigational immunotherapy Multikine*...

CEL-SCI Granted European Patent For Multikine Cancer Immunotherapy In Combination With Radiation And/or Chemotherapy

CEL-SCI Granted European Patent For Multikine Cancer Immunotherapy In Combination With Radiation And/or Chemotherapy

CEL-SCI Corporation ( NYSE MKT: CVM ) announces that it has been granted a new European patent covering its investigational Phase 3 cancer immunotherapy drug Multikine* (Leucocyte Interleukin).

CEL-SCI Reports Monthly Patient Enrollment In June For Its Phase 3 Head And Neck Cancer Trial

CEL-SCI Reports Monthly Patient Enrollment In June For Its Phase 3 Head And Neck Cancer Trial

CEL-SCI Corporation (NYSE MKT: CVM) ("CEL SCI" or the "Company") today announced that during the month of June it has enrolled 32 patients in its ongoing Phase 3 trial of its investigational immunotherapy Multikine*...

CEL-SCI Reports Monthly Patient Enrollment In May For Its Phase 3 Head And Neck Cancer Trial

CEL-SCI Reports Monthly Patient Enrollment In May For Its Phase 3 Head And Neck Cancer Trial

CEL-SCI Corporation (NYSE MKT: CVM) ("CEL SCI" or the "Company") today announced that during the month of May it has enrolled 19 patients in its ongoing Phase 3 trial of its investigational immunotherapy Multikine*...

CEL-SCI To Present At The Fifth Annual Marcum MicroCap Conference

CEL-SCI To Present At The Fifth Annual Marcum MicroCap Conference

CEL-SCI Corporation (NYSE MKT: CVM), a late-stage cancer immunotherapy company, announced today that it will be a featured presenter at the 5th Annual Marcum MicroCap Conference on Thursday, June 2, 2016 in New York City...

CEL-SCI Announces The Closing Of Its $5 Million Registered Direct Offering

CEL-SCI Announces The Closing Of Its $5 Million Registered Direct Offering

CEL-SCI Corporation (NYSE MKT: CVM) today announced that it has closed its previously announced registered direct offering with a single healthcare dedicated institutional investor.

CEL-SCI Announces $5 Million Registered Direct Offering

CEL-SCI Announces $5 Million Registered Direct Offering

CEL-SCI Corporation (NYSE MKT: CVM) today announced it has entered into a definitive agreement with a single healthcare dedicated institutional investor to purchase approximately 10 million shares of its common stock and...

CEL-SCI Corporation Reports Second Quarter Fiscal Year 2016 Financial Results

CEL-SCI Corporation Reports Second Quarter Fiscal Year 2016 Financial Results

CEL-SCI Corporation (NYSE MKT: CVM) today reported financial results for the quarter ended March 31, 2016.

CEL-SCI Reports Record Monthly Patient Enrollment In April For Its Phase 3 Head And Neck Cancer Trial

CEL-SCI Reports Record Monthly Patient Enrollment In April For Its Phase 3 Head And Neck Cancer Trial

CEL-SCI Corporation (NYSE MKT:CVM) ("CEL SCI" or the "Company") today announced that during the month of April it has enrolled 41 patients in its ongoing Phase 3 trial of its investigational immunotherapy Multikine*...

CEL-SCI Featured On The RedChip Money Report Airing On Newsmax TV

CEL-SCI Featured On The RedChip Money Report Airing On Newsmax TV

CEL-SCI Corporation (NYSE MKT:CVM) announced today that its CEO, Geert Kersten, was recently interviewed on The RedChip Money Report television program.

CEL-SCI Reports Monthly Patient Enrollment In March For Its Phase 3 Head And Neck Cancer Trial

CEL-SCI Reports Monthly Patient Enrollment In March For Its Phase 3 Head And Neck Cancer Trial

CEL-SCI Corporation (NYSE MKT: CVM) ("CEL SCI" or the "Company") today announced that during the month of March it has enrolled 32 patients in its ongoing Phase 3 trial of its investigational immunotherapy...

CEL-SCI Reports Monthly Patient Enrollment In February For Its Phase 3 Head And Neck Cancer Trial

CEL-SCI Reports Monthly Patient Enrollment In February For Its Phase 3 Head And Neck Cancer Trial

CEL-SCI Corporation (NYSE MKT: CVM) ("CEL SCI" or the "Company") today announced that during the month of February it has enrolled 27 patients in its ongoing Phase 3 trial of its investigational immunotherapy...

CEO Geert Kersten Summarizes CEL-SCI's Phase 3 Cancer Immunotherapy Progress In A New Video Interview

CEO Geert Kersten Summarizes CEL-SCI's Phase 3 Cancer Immunotherapy Progress In A New Video Interview

CEL-SCI Corporation (NYSE MKT:CVM) announced today that a new video interview with Geert Kersten, Chief Executive Officer, is available for viewing.

CEL-SCI CEO Geert Kersten Was A Featured Guest On Fox Business' Making Money With Charles Payne

CEL-SCI CEO Geert Kersten Was A Featured Guest On Fox Business' Making Money With Charles Payne

CEL-SCI Corporation (NYSE MKT:CVM) announced today that its Chief Executive Officer Geert Kersten was a guest on Fox Business' Making Money with Charles Payne.

CEL-SCI Corporation Reports First Quarter Fiscal 2016 Financial Results

CEL-SCI Corporation Reports First Quarter Fiscal 2016 Financial Results

CEL-SCI Corporation (NYSE MKT: CVM) today reported financial results for the quarter ended December 31, 2015.

CEL-SCI To Present At Source Capital Group's 2016 Disruptive Growth & Healthcare Conference

CEL-SCI To Present At Source Capital Group's 2016 Disruptive Growth & Healthcare Conference

CEL-SCI Corporation (NYSE MKT: CVM) announced today that Geert Kersten, Chief Executive officer, will provide a company overview at the Source Capital Group's 2016 Disruptive Growth & Healthcare Conference on...

CEL-SCI To Present At 18th Annual BIO CEO & Investor Conference

CEL-SCI To Present At 18th Annual BIO CEO & Investor Conference

CEL-SCI Corporation (NYSE MKT: CVM) announced that Geert Kersten, Chief Executive Officer, will be presenting at the 18 th Annual BIO CEO & Investor Conference on Tuesday, February 9, 2016 at 11:00 a.

CEL-SCI Reports Monthly Patient Enrollment In January For Its Phase 3 Head And Neck Cancer Trial

CEL-SCI Reports Monthly Patient Enrollment In January For Its Phase 3 Head And Neck Cancer Trial

CEL-SCI Corporation (NYSE MKT: CVM) ("CEL SCI" or the "Company") today announced that during the month of January it has enrolled 29 patients in its ongoing Phase 3 trial of its investigational immunotherapy...

CEL-SCI's Chief Scientific Officer Discusses Cancer Immunotherapy Multikine

CEL-SCI's Chief Scientific Officer Discusses Cancer Immunotherapy Multikine

CEL-SCI Corporation (NYSE MKT: CVM) Chief Scientific Officer, Eyal Talor, Ph.

CEL-SCI Corporation To Present At The Noble Financial Capital Markets' 12th Annual Investor Conference

CEL-SCI Corporation To Present At The Noble Financial Capital Markets' 12th Annual Investor Conference

CEL-SCI Corporation (NYSE MKT: CVM), a Phase 3 cancer immunotherapy company, today announced that its Chief Executive Officer, Geert Kersten, will present at the NobleCon12 - Noble Financial Capital Markets' Twelfth Annual...

CEL-SCI Corporation Summarizes Significant Accomplishments In 2015 And Positive Momentum For 2016

CEL-SCI Corporation Summarizes Significant Accomplishments In 2015 And Positive Momentum For 2016

The following letter is being released by CEL-SCI Corporation (NYSE MKT: CVM) to its shareholders: Dear Fellow Shareholders: As CEL-SCI shareholders most of you have been following the progress in our...

CEL-SCI Reports Record Year For Patient Enrollment With 75% Increase In Its Global Phase 3 Head And Neck Cancer Trial

CEL-SCI Reports Record Year For Patient Enrollment With 75% Increase In Its Global Phase 3 Head And Neck Cancer Trial

CEL-SCI Corporation (NYSE MKT: CVM) ("CEL SCI" or the "Company") today announced that in 2015 it enrolled 340 patients in its ongoing Phase 3 trial of its investigational immunotherapy Multikine* (Leukocyte...

CEL-SCI Reports Fiscal 2015 Financial Results And Clinical & Corporate Developments

CEL-SCI Reports Fiscal 2015 Financial Results And Clinical & Corporate Developments

CEL-SCI Corporation (NYSE MKT: CVM) ("CEL SCI" or the "Company") reported financial results today for the fiscal year ended September 30, 2015.

CEL-SCI's CEO Presentation Available On Company Website

CEL-SCI's CEO Presentation Available On Company Website

CEL-SCI Corporation (NYSE MKT: CVM), a late-stage oncology company, announced that the presentation made by Geert Kersten, Chief Executive Officer of CEL-SCI, at the 8 th annual LD Micro Main Event on Thursday,...

CEL-SCI Reports Monthly Patient Enrollment In November For Its Phase 3 Head And Neck Cancer Trial

CEL-SCI Reports Monthly Patient Enrollment In November For Its Phase 3 Head And Neck Cancer Trial

CEL-SCI Corporation (NYSE MKT: CVM) ("CEL SCI" or the "Company") today announced that in the month of November it has enrolled 27 patients in its ongoing Phase 3 trial of its investigational immunotherapy Multikine*...